Fong I W, Rittenhouse B R, Simbul M, Vandenbroucke A C
Department of Medicine, St. Michael's Hospital, University of Toronto, Ontario, Canada.
Antimicrob Agents Chemother. 1988 Jun;32(6):834-7. doi: 10.1128/AAC.32.6.834.
Enoxacin concentrations in bone were measured in 24 patients without infection and in 7 with osteomyelitis after one or two doses of 400 mg of enoxacin administered orally or intravenously. Enoxacin concentrations were measured in serum and bone (cortical and cancellous) by high-pressure liquid chromatography. The mean concentration in serum was 2.4 +/- 1.0 micrograms/ml (range, 1.3 to 5.2 micrograms/ml) and was highest after two intravenous doses (3.1 +/- 0.9 micrograms/ml). The mean concentration in cortical bone was 1.0 +/- 0.9 micrograms/g (range, 0.4 to 4.8 micrograms/g) and was highest in patients with osteomyelitis (1.3 +/- 1.6 micrograms/g), but this was not statistically significant. The concentration of enoxacin in cancellous bone was significantly higher than that in cortical bone, with a penetration of 82 versus 40%. Oral enoxacin in practical doses can provide significant levels in bone, and further studies are warranted to determine its therapeutic efficacy in osteomyelitis.
对24名无感染患者和7名患有骨髓炎的患者口服或静脉注射一剂或两剂400毫克依诺沙星后,测量其骨中的依诺沙星浓度。通过高压液相色谱法测量血清和骨(皮质骨和松质骨)中的依诺沙星浓度。血清中的平均浓度为2.4±1.0微克/毫升(范围为1.3至5.2微克/毫升),在两次静脉给药后最高(3.1±0.9微克/毫升)。皮质骨中的平均浓度为1.0±0.9微克/克(范围为0.4至4.8微克/克),在骨髓炎患者中最高(1.3±1.6微克/克),但这在统计学上无显著意义。松质骨中依诺沙星的浓度明显高于皮质骨,渗透率分别为82%和40%。实际剂量的口服依诺沙星可在骨中达到显著水平,有必要进行进一步研究以确定其对骨髓炎的治疗效果。